FDA
-
-
-
-
-
-
-
Indivior PLC to Acquire Opiant Pharmaceuticals
-
-
-
-
-
-
-
Opiant Pharmaceuticals (OPNT) Granted US Patent With Claims Covering OPNT003
-
-
-
-
-
-
-
Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
-
-
-
-
-
-
-
Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
-
-
-
-
-
-
-
Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose
-
251,576 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All